NYSE:MRK - Merck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MRK stock has decreased by 2.9% and is now trading at $76.95. View which stocks have been mosted impacted by Coronavirus.

16 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 4 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Tuesday, April 28th 2020. View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Tuesday, April 28th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) issued its quarterly earnings results on Wednesday, February, 5th. The company reported $1.16 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.15 by $0.01. The business had revenue of $11.87 billion for the quarter, compared to the consensus estimate of $11.71 billion. Merck & Co., Inc. had a net margin of 21.01% and a return on equity of 49.41%. The firm's revenue was up 7.9% compared to the same quarter last year. During the same period last year, the company posted $1.04 earnings per share. View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Wednesday, January 29th. Investors of record on Monday, March 16th will be given a dividend of $0.61 per share on Tuesday, April 7th. This represents a $2.44 dividend on an annualized basis and a yield of 3.17%. The ex-dividend date of this dividend is Friday, March 13th. View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. announced that its board has initiated a share repurchase plan on Thursday, October 25th 2018, which allows the company to buyback $10,000,000,000.00 in shares, according to EventVestor. This buyback authorization allows the company to reacquire up to 5.1% of its stock through open market purchases. Stock buyback plans are usually an indication that the company's board of directors believes its shares are undervalued.

Merck & Co., Inc. updated its FY20 earnings guidance on Wednesday, February, 5th. The company provided EPS guidance of $5.62-5.77 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.54. The company issued revenue guidance of $48.8-50.3 billion, compared to the consensus revenue estimate of $48.65 billion.

16 brokers have issued 12-month price targets for Merck & Co., Inc.'s shares. Their forecasts range from $84.00 to $105.00. On average, they expect Merck & Co., Inc.'s stock price to reach $94.60 in the next twelve months. This suggests a possible upside of 22.9% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

Press coverage about MRK stock has trended very negative this week, InfoTrie Sentiment Analysis reports. The research group identifies positive and negative media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Merck & Co., Inc. earned a media sentiment score of -3.7 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. View the latest news aboutMerck & Co., Inc..

Merck & Co., Inc. saw a drop in short interest during the month of March. As of March 13th, there was short interest totaling 18,162,700 shares, a drop of 12.6% from the February 27th total of 20,780,000 shares. Based on an average daily trading volume, of 10,770,000 shares, the short-interest ratio is presently 1.7 days. Currently, 0.7% of the company's stock are sold short. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Mylan (MYL), Perrigo (PRGO), Horizon Therapeutics (HZNP), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX).

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include AT&T (T), Pfizer (PFE), Johnson & Johnson (JNJ), Walt Disney (DIS), Cisco Systems (CSCO), Intel (INTC), Verizon Communications (VZ), JPMorgan Chase & Co. (JPM), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $76.95.

Merck & Co., Inc. has a market capitalization of $195.17 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe. View additional information about Merck & Co., Inc..

The official website for Merck & Co., Inc. is http://www.merck.com/.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]